Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Receivables (2016 - 2025)

Historic Receivables for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to $676000.0.

  • Lineage Cell Therapeutics' Receivables rose 6691.36% to $676000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $676000.0, marking a year-over-year increase of 6691.36%. This contributed to the annual value of $638000.0 for FY2024, which is 1436.24% down from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Receivables stood at $676000.0, which was up 6691.36% from $256000.0 recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Receivables peaked at $51.2 million during Q4 2021, and registered a low of $77000.0 during Q1 2024.
  • In the last 5 years, Lineage Cell Therapeutics' Receivables had a median value of $432000.0 in 2023 and averaged $3.1 million.
  • The largest annual percentage gain for Lineage Cell Therapeutics' Receivables in the last 5 years was 127927500.0% (2021), contrasted with its biggest fall of 9954.66% (2021).
  • Over the past 5 years, Lineage Cell Therapeutics' Receivables (Quarter) stood at $51.2 million in 2021, then crashed by 98.28% to $881000.0 in 2022, then dropped by 15.44% to $745000.0 in 2023, then dropped by 14.36% to $638000.0 in 2024, then rose by 5.96% to $676000.0 in 2025.
  • Its Receivables stands at $676000.0 for Q3 2025, versus $256000.0 for Q2 2025 and $213000.0 for Q1 2025.